Publications by authors named "S Stander"
Importance: Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in itch and skin nodules in adults with moderate to severe PN in a previous 16-week phase 3 study (OLYMPIA 2).
Objective: To assess the efficacy and occurrence of adverse events in adults with moderate to severe PN treated with nemolizumab vs those receiving placebo.
The occurrence of pruritus in psoriasis was previously underestimated but is a significant burden. Secukinumab (SEC), a monoclonal anti-interleukin-17A antibody, efficiently controls signs of psoriasis, but the effect on pruritus and cutaneous neuroanatomy remained unknown. The primary objective of this study (NCT02362789) was to evaluate the superiority of SEC treatment vs placebo on pruritus intensity (visual analogue scale; VAS).
View Article and Find Full Text PDFArticle Synopsis
- Hidradenitis suppurativa (HS) can greatly impact patients' quality of life due to its association with psychological issues like anxiety and depression, often intensified by stigmatization related to physical appearance.
- A study involving 135 HS patients from 22 dermatology clinics in Europe found significant levels of perceived stigmatization, which correlated with disease duration, itchiness, and depression symptoms.
- The research emphasizes the need for comprehensive management of HS, including addressing psychological well-being and access to mental health support for better patient outcomes.
Article Synopsis
- The study analyzed the long-term safety of dupilumab, a drug for atopic dermatitis (AD), compared to conventional systemic treatments like azathioprine and methotrexate using electronic health records.
- Findings showed that dupilumab had a lower risk of various adverse effects, including infections and type 2 inflammatory diseases, compared to other treatments.
- However, the risk of conjunctivitis was higher in patients treated with dupilumab compared to those on mycophenolate mofetil and methotrexate, prompting the need for further research to confirm these results.
Background: Vitiligo is an autoimmune disease, characterized by specific destruction of melanocytes. While associations with numerous comorbid conditions, which potentially increase the risk of cardiovascular diseases have been described, data on the risk for cardiovascular disease is inconclusive. To address this relevant knowledge gap, this study aims to identify the risk of cardiovascular disease in vitiligo.
View Article and Find Full Text PDF